Phase
Condition
Infertility
Female Hormonal Deficiencies/abnormalities
Treatment
N/AClinical Study ID
Ages 18-45 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Ovulatory dysfunction as evidenced by mid-luteal progesterone less then 3ng/dL,non-biphasic basal body temperature charting, or menstrual history of cycles > 35days.
Female patients 18 to 45 years old
Six months or greater of unprotected intercourse without pregnancy.
Normal TSH and prolactin serum levels
Semen analysis of male partner with > 15 million motile sperm on semen analysis.
NOTE: Must be willing to travel to the Oklahoma City area for treatment.
Exclusion
Exclusion Criteria:
Failure to spontaneously menstruate or to menstruate following progestinadministration
Allergy or intolerance to the side effects of clomiphene citrate, hCG (human chorionicgonadotropins), or medroxyprogesterone acetate (Provera).
Known anatomical defect affecting the uterine cavity including submucosal fibroids orendometrial polyps.
Know tubal hydrosalpinx or risk factors for tubal obstruction
Known liver dysfunction
Known or suspected androgen secreting tumor, cushings disease, or adrenal hyperplasia (congenital or adult onset)
Ovarian cyst > 20mm or endometrial lining >6 mm on trans-vaginal baseline ultrasound.
Stage III or IV endometriosis
Decreased ovarian reserve as evidenced by antral follicle count less than 6 byTransvaginal ultrasound or a cycle-day-3 serum FSH of > 10 uIU/ml.
Positive HIV in either the female patient or her partner.
Study Design
Study Description
Connect with a study center
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma 73013
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.